Wealthfront Advisers
REGN icon

Wealthfront Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealthfront Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37M Sell
7,006
-1,338
-16% -$911K 0.01% 460
2026
Q1 		$6.45M Buy
8,344
+202
+2% +$155K 0.01% 365
2025
Q4 		$6.28M Buy
8,142
+2,202
+37% +$1.5M 0.01% 348
2025
Q3 		$3.34M Buy
5,940
+1,325
+29% +$749K 0.01% 475
2025
Q2 		$2.42M Sell
4,615
-1,560
-25% -$871K 0.01% 530
2025
Q1 		$3.92M Sell
6,175
-1,173
-16% -$807K 0.01% 403
2024
Q4 		$5.23M Sell
7,348
-2,141
-23% -$1.8M 0.02% 320
2024
Q3 		$9.98M Sell
9,489
-97
-1% -$108K 0.03% 165
2024
Q2 		$10.1M Sell
9,586
-154
-2% -$149K 0.03% 152
2024
Q1 		$9.37M Buy
9,740
+129
+1% +$123K 0.03% 151
2023
Q4 		$8.44M Buy
9,611
+145
+2% +$119K 0.03% 151
2023
Q3 		$7.79M Sell
9,466
-1,179
-11% -$927K 0.03% 153
2023
Q2 		$7.65M Sell
10,645
-5,943
-36% -$4.58M 0.03% 157
2023
Q1 		$13.6M Buy
16,588
+6,294
+61% +$4.75M 0.06% 87
2022
Q4 		$7.43M Sell
10,294
-75
-0.7% -$55.3K 0.04% 147
2022
Q3 		$7.14M Buy
10,369
+1,749
+20% +$1.1M 0.04% 127
2022
Q2 		$5.1M Buy
8,620
+4,881
+131% +$3.17M 0.03% 181
2022
Q1 		$2.61M Buy
3,739
+40
+1% +$25.3K 0.01% 339
2021
Q4 		$2.34M Buy
3,699
+130
+4% +$79.9K 0.01% 348
2021
Q3 		$2.16M Buy
3,569
+76
+2% +$47.2K 0.01% 331
2021
Q2 		$1.95M Sell
3,493
-2,990
-46% -$1.51M 0.01% 311
2021
Q1 		$3.07M Sell
6,483
-1,221
-16% -$594K 0.02% 178
2020
Q4 		$3.72M Buy
7,704
+3,301
+75% +$1.78M 0.02% 125
2020
Q3 		$2.46M Sell
4,403
-678
-13% -$411K 0.02% 146
2020
Q2 		$3.17M Buy
5,081
+4,205
+480% +$2.39M 0.02% 110
2020
Q1 		$428K Buy
876
+165
+23% +$68.1K ﹤0.01% 363
2019
Q4 		$267K Buy
+711
New +$239K ﹤0.01% 458
2019
Q3 		– Sell
-1,324
Closed -$414K – 487
2019
Q2 		$414K Sell
1,324
-166
-11% -$55.3K ﹤0.01% 406
2019
Q1 		$612K Buy
1,490
+439
+42% +$181K 0.01% 335
2018
Q4 		$393K Buy
+1,051
New +$385K ﹤0.01% 368

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealthfront Advisers's REGN Position: Q2 2026 in Review

Wealthfront Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $911K and leaving 7,006 shares worth $4.37M. The position accounts for 0.01% of the portfolio, ranked #460.

Wealthfront Advisers first reported a position in REGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $13.6M in Q1 2023. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Wealthfront Advisers held 7,006 shares of Regeneron Pharmaceuticals worth $4.37M as of Q2 2026.
  • Wealthfront Advisers sold 1,338 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $911K.
  • Regeneron Pharmaceuticals made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #460 holding.
  • Wealthfront Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Wealthfront Advisers's Regeneron Pharmaceuticals position peaked at $13.6M in Q1 2023.
  • 955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.